| |
| |
|
| Insider
Information: |
Bishop Hans Edgar |
| Relationship: |
Director |
| City: |
Seattle |
| State: |
WA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
10,734,769 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$15,746,079 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
10,734,769 |
|
|
| Total
Value |
$15,746,079 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Dendreon Corp |
DNDN |
Chief Operating Officer |
2011-07-29 |
151,189 |
2010-01-29 |
0 |
Premium* |
|
|
Avanir Pharmaceuticals |
AVNR |
Director |
2014-02-12 |
93,350 |
2013-02-14 |
0 |
Premium* |
|
|
Juno Therapeutics, Inc. |
JUNO |
CEO & President, Direc... |
2018-03-05 |
0 |
|
0 |
Premium* |
|
|
Agilent Technologies Inc |
A |
Director |
2024-03-15 |
24,976 |
2017-07-18 |
0 |
Premium* |
|
|
Celgene Corp |
CELG |
|
2019-11-20 |
0 |
2019-11-20 |
0 |
Premium* |
|
|
Sana Biotechnology, Inc. |
SANA |
|
2024-04-05 |
5,779,640 |
|
0 |
Premium* |
|
|
Lyell Immunopharma, Inc. |
LYEL |
Director |
2022-09-08 |
4,685,614 |
2021-06-21 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| JUNO |
Juno Therapeutics, Inc. |
CEO & President |
• • – |
2018-03-05 |
4 |
D |
$87.00 |
$196,963,476 |
D/D |
(2,263,948) |
184,281 |
0 |
- |
|
| SANA |
Sana Biotechnology, Inc. |
Director |
– • – |
2021-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
2,031,250 |
5,736,250 |
0 |
- |
|
| LYEL |
Lyell Immunopharma, Inc. |
Director |
– • – |
2022-02-23 |
4 |
OE |
$0.10 |
$99,343 |
D/D |
993,428 |
4,540,234 |
0 |
- |
|
| LYEL |
Lyell Immunopharma, Inc. |
Director |
– • – |
2021-06-21 |
4 |
A |
$0.00 |
$0 |
D/D |
546,806 |
3,546,806 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO & President |
• • – |
2018-01-16 |
4 |
AS |
$44.72 |
$12,478,528 |
D/D |
(270,250) |
2,502,429 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO & President |
• • – |
2018-01-16 |
4 |
OE |
$6.36 |
$1,562,970 |
D/D |
245,750 |
2,772,679 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO & President |
• • – |
2018-03-05 |
4 |
D |
$0.00 |
$4,248,123 |
D/D |
(184,281) |
0 |
0 |
- |
|
| LYEL |
Lyell Immunopharma, Inc. |
Director |
– • – |
2022-09-08 |
4 |
OE |
$0.10 |
$14,538 |
D/D |
145,380 |
4,685,614 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO & President |
• • – |
2018-02-07 |
4 |
GD |
$0.00 |
$0 |
D/D |
116,280 |
2,448,229 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO & President |
• • – |
2016-06-30 |
4/A |
AS |
$38.41 |
$4,431,116 |
D/D |
(115,250) |
2,542,609 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO & President |
• • – |
2016-06-30 |
4 |
D |
$38.41 |
$4,431,116 |
D/D |
(115,250) |
2,542,609 |
0 |
- |
|
| DNDN |
Dendreon Corp |
Chief Operating Officer |
• – – |
2010-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
110,000 |
110,000 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO and President |
• • – |
2015-12-15 |
4 |
AS |
$44.77 |
$4,183,411 |
D/D |
(91,500) |
2,687,359 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
See Remarks |
• • – |
2016-02-29 |
4 |
AS |
$35.27 |
$3,205,005 |
D/D |
(90,750) |
2,650,609 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO & President |
• • – |
2016-06-09 |
4 |
AS |
$45.80 |
$4,212,344 |
D/D |
(90,750) |
2,613,859 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO & President |
• • – |
2016-09-21 |
4 |
AS |
$30.30 |
$2,342,588 |
D/D |
(77,307) |
2,446,859 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO & President |
• • – |
2018-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
66,426 |
2,568,855 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO and President |
• • – |
2015-12-15 |
4 |
OE |
$6.36 |
$343,440 |
D/D |
54,000 |
2,778,859 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
See Remarks |
• • – |
2016-02-29 |
4 |
OE |
$6.36 |
$343,440 |
D/D |
54,000 |
2,741,359 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO & President |
• • – |
2016-06-09 |
4 |
OE |
$6.36 |
$343,440 |
D/D |
54,000 |
2,704,609 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO & President |
• • – |
2017-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
44,177 |
2,491,036 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO & President |
• • – |
2016-06-30 |
4 |
OE |
$6.36 |
$279,840 |
D/D |
44,000 |
2,657,859 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO & President |
• • – |
2016-09-27 |
4 |
AS |
$33.00 |
$1,452,000 |
D/D |
(44,000) |
2,446,859 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO & President |
• • – |
2016-09-27 |
4 |
OE |
$6.36 |
$279,840 |
D/D |
44,000 |
2,490,859 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO & President |
• • – |
2016-08-31 |
4 |
AS |
$30.06 |
$1,282,554 |
D/D |
(42,673) |
2,518,109 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
